Literature DB >> 17978156

Endogenous lipid mediators in the resolution of airway inflammation.

O Haworth1, B D Levy.   

Abstract

Acute inflammation in the lung is fundamentally important to host defence, but chronic or excessive inflammation leads to several common respiratory diseases, including asthma and acute respiratory distress syndrome. The resolution of inflammation is an active process. In health, events at the onset of acute inflammation establish biosynthetic circuits for specific chemical mediators that later serve as agonists to orchestrate a return to tissue homeostasis. In addition to an overabundance of pro-inflammatory stimuli, pathological inflammation can also result from defects in resolution signalling. The understanding of anti-inflammatory, pro-resolution molecules and their counter-regulatory signalling pathways is providing new insights into the molecular pathophysiology of lung disease and opportunities for the design of therapeutic strategies. In the present review, the growing family of lipid mediators of resolution is examined, including lipoxins, resolvins, protectins, cyclopentenones and presqualene diphosphate. Roles are uncovered for these compounds, or their structural analogues, in regulating airway inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978156      PMCID: PMC3005702          DOI: 10.1183/09031936.00005807

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  143 in total

Review 1.  Inflammatory resolution: new opportunities for drug discovery.

Authors:  Derek W Gilroy; Toby Lawrence; Mauro Perretti; Adriano G Rossi
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4).

Authors:  Bruce D Levy; George T De Sanctis; Pallavi R Devchand; Eugene Kim; Kate Ackerman; Birgitta A Schmidt; Wojciech Szczeklik; Jeffrey M Drazen; Charles N Serhan
Journal:  Nat Med       Date:  2002-08-12       Impact factor: 53.440

3.  A stable aspirin-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils.

Authors:  Taisuke Ohira; Gerard Bannenberg; Makoto Arita; Minoru Takahashi; Qingyuan Ge; Thomas E Van Dyke; Gregory L Stahl; Charles N Serhan; John A Badwey
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

4.  Association of cystic fibrosis with abnormalities in fatty acid metabolism.

Authors:  Steven D Freedman; Paola G Blanco; Munir M Zaman; Julie C Shea; Mario Ollero; Isabel K Hopper; Deborah A Weed; Andres Gelrud; Meredith M Regan; Michael Laposata; Juan G Alvarez; Brian P O'Sullivan
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

5.  Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids.

Authors:  Jing X Kang; Jingdong Wang; Lin Wu; Zhao B Kang
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

6.  Topical glucocorticoid therapy directly induces up-regulation of functional CXCR4 on primed T lymphocytes in the aqueous humor of patients with uveitis.

Authors:  S John Curnow; Kaska Wloka; Jeff M Faint; Nicole Amft; C M Gemmy Cheung; Vijay Savant; Janet Lord; Arne N Akbar; Christopher D Buckley; Philip I Murray; Mike Salmon
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

7.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

Authors:  Christopher L Karp; Leah M Flick; Kiwon W Park; Samir Softic; Todd M Greer; Raquel Keledjian; Rong Yang; Jasim Uddin; William B Guggino; Sowsan F Atabani; Yasmine Belkaid; Yan Xu; Jeffrey A Whitsett; Frank J Accurso; Marsha Wills-Karp; Nicos A Petasis
Journal:  Nat Immunol       Date:  2004-03-21       Impact factor: 25.606

8.  15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation.

Authors:  Mark J Paul-Clark; Thong Van Cao; Niloufar Moradi-Bidhendi; Dianne Cooper; Derek W Gilroy
Journal:  J Exp Med       Date:  2004-07-05       Impact factor: 14.307

9.  Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.

Authors:  Charles N Serhan; Song Hong; Karsten Gronert; Sean P Colgan; Pallavi R Devchand; Gudrun Mirick; Rose-Laure Moussignac
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

10.  Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.

Authors:  Mauro Perretti; Nan Chiang; Mylinh La; Iolanda M Fierro; Stefano Marullo; Stephen J Getting; Egle Solito; Charles N Serhan
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  34 in total

1.  Pediatric Respiratory Assembly. Mini symposium on lung inflammation.

Authors:  Larry C Lands; A Keith Tanswell; Sophie Laberge; Christine McCusker; Felix Ratjen
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

2.  Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production.

Authors:  Marion Man-Ying Chan; Andrea Rossi Moore
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

3.  Novel cellular targets of AhR underlie alterations in neutrophilic inflammation and inducible nitric oxide synthase expression during influenza virus infection.

Authors:  Jennifer L Head Wheeler; Kyle C Martin; B Paige Lawrence
Journal:  J Immunol       Date:  2012-12-10       Impact factor: 5.422

4.  PPARγ inhibits airway epithelial cell inflammatory response through a MUC1-dependent mechanism.

Authors:  Yong Sung Park; Erik P Lillehoj; Kosuke Kato; Choon Sik Park; Kwang Chul Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-20       Impact factor: 5.464

5.  Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease.

Authors:  Steven Bozinovski; Mohib Uddin; Ross Vlahos; Michelle Thompson; Jonathan L McQualter; Anne-Sophie Merritt; Peter A B Wark; Anastasia Hutchinson; Louis B Irving; Bruce D Levy; Gary P Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-03       Impact factor: 11.205

6.  Anti-Inflammatory Effects of OxPAPC Involve Endothelial Cell-Mediated Generation of LXA4.

Authors:  Yunbo Ke; Noureddine Zebda; Olga Oskolkova; Taras Afonyushkin; Evgeny Berdyshev; Yufeng Tian; Fanyong Meng; Nicolene Sarich; Valery N Bochkov; Ji Ming Wang; Anna A Birukova; Konstantin G Birukov
Journal:  Circ Res       Date:  2017-05-18       Impact factor: 17.367

7.  Ultraperformance convergence chromatography-high resolution tandem mass spectrometry for lipid biomarker profiling and identification.

Authors:  Jace W Jones; Claire L Carter; Fei Li; Jianshi Yu; Keely Pierzchalski; Isabel L Jackson; Zeljko Vujaskovic; Maureen A Kane
Journal:  Biomed Chromatogr       Date:  2016-09-29       Impact factor: 1.902

8.  Attenuation of lipopolysaccharide-induced lung vascular stiffening by lipoxin reduces lung inflammation.

Authors:  Fanyong Meng; Isa Mambetsariev; Yufeng Tian; Yvonne Beckham; Angelo Meliton; Alan Leff; Margaret L Gardel; Michael J Allen; Konstantin G Birukov; Anna A Birukova
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

9.  Interleukin-13-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells.

Authors:  Jinming Zhao; Ben Maskrey; Silvana Balzar; Kazuyuki Chibana; Anthony Mustovich; Haizhen Hu; John B Trudeau; Valerie O'Donnell; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

Review 10.  Biomarkers in asthma: a real hope to better manage asthma.

Authors:  Serpil C Erzurum; Benjamin M Gaston
Journal:  Clin Chest Med       Date:  2012-07-25       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.